Table 2.
Pattern of failure, survival and second primary lung cancer over 7 years after stereotactic ablative radiotherapy
| Eventa | Actual incidence (%) | Estimated cumulative incidence, % (95% CI) | |||
|---|---|---|---|---|---|
|
| |||||
| 1-year | 3-year | 5-year | 7-year | ||
| Local recurrence | 7.7 | 1.5 (0.2–10.8) | 4.6 (1.5–13.9) | 8.1 (3.5–18.8) | 8.1 (3.5–18.8) |
| Regional recurrence | 12.3 | 4.6 (1.5–13.9) | 9.2 (4.3–19.8) | 10.9 (5.4–21.8) | 13.6 (7.0–26.5) |
| Loco-regional recurrence | 18.5 | 6.2 (2.4–15.9) | 12.3 (6.4–23.6) | 17.4 (10.1–29.8) | 20.0 (11.9–33.7) |
| Distant metastases | 12.3 | 7.7 (3.3–17.9) | 9.2 (4.3–17.8) | 11.0 (5.5–22.2) | 13.8 (7.1–26.8) |
| Any recurrence | 27.7 | 12.3 (6.4–23.6) | 18.5 (11.1–30.8) | 25.3 (16.6–38.8) | 30.9 (20.7–46.0) |
| Progression-free survivalb | - | 81.5 (76.7–86.3) | 64.6 (58.7–70.5) | 49.5 (43.2–55.8) | 38.2 (31.2–45.2) |
| Overall survivalb | - | 92.3 (89.0–95.6) | 70.8 (65.2–76.4) | 55.7 (49.4–62.0) | 47.5 (40.6–54.4) |
| Second primary lung cancer | 18.5 | 4.6 (1.5–13.9) | 9.2 (4.3–19.8) | 16.2 (9.2–28.6) | 20.7 (12.4–34.5) |
a
Any recurrence as the first event was calculated, and subsequent recurrence was not estimated here. The cumulative competing risk method was used to estimate the probabilities of any recurrence in the presence of competing risks (any cause of death).
b
Progression-free survival and overall survival were calculated using the conventional Kaplan-Meier method.